Tahmoush Albert J, Amir Mary S, Connor William W, Farry James K, Didato Sevastian, Ulhoa-Cintra Alice, Vasas Jennifer M, Schwartzman Robert J, Israel Harold L, Patrick Herbert
Department of Neurology, MCP Hahnemann University, Philadelphia, PA 19102, USA.
Sarcoidosis Vasc Diffuse Lung Dis. 2002 Oct;19(3):191-7.
To redefine the utility of CSF-ACE as a selective indicator of probable CNS neurosarcoidosis.
The diagnosis of probable CNS neurosarcoidosis required: (a) biopsy evidence of systemic sarcoidosis, (b) cortical, brainstem, and/or spinal cord deficits, (c) enhancing lesions on brain and/or spinal cord MRI, and (d) exclusion of other etiologies which could account for the neurological deficits. Radioassay measurement of CSF-ACE activity was performed in 11 patients who met our criteria for probable CNS neurosarcoidosis and 207 control patients.
The M +/- SD for CSF-ACE activity was significantly higher (p < 0.05) for the 11 probable CNS neurosarcoidosis patients (9.5 +/- 6.9 nmol/mL/min) than for the control patients (2.9 +/- 2.7 nmol/mL/min). The optimal CSF-ACE activity discriminator value was 8 nmol/mL/min. At this value, the sensitivity and specificity of CSF-ACE activity was 55% and 94%, respectively.
CSF-ACE activity is a useful biochemical marker of probable CNS neurosarcoidosis when brain and/or spinal cord MRI show diffuse enhancing lesions.
重新界定脑脊液血管紧张素转换酶(CSF-ACE)作为可能的中枢神经系统结节病选择性指标的效用。
可能的中枢神经系统结节病的诊断需要:(a)系统性结节病的活检证据,(b)皮质、脑干和/或脊髓功能缺损,(c)脑和/或脊髓磁共振成像(MRI)上的强化病变,以及(d)排除其他可解释神经功能缺损的病因。对11例符合我们可能的中枢神经系统结节病标准的患者和207例对照患者进行了脑脊液血管紧张素转换酶活性的放射免疫测定。
11例可能的中枢神经系统结节病患者的脑脊液血管紧张素转换酶活性的均值±标准差(M±SD)(9.5±6.9纳摩尔/毫升/分钟)显著高于对照患者(2.9±2.7纳摩尔/毫升/分钟)(p<0.05)。脑脊液血管紧张素转换酶活性的最佳鉴别值为8纳摩尔/毫升/分钟。在此值时,脑脊液血管紧张素转换酶活性的敏感性和特异性分别为55%和94%。
当脑和/或脊髓MRI显示弥漫性强化病变时,脑脊液血管紧张素转换酶活性是可能的中枢神经系统结节病的有用生化标志物。